Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Hospital Clínic of Barcelona (BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine), Fetal I+D Fetal Medicine Research Center, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Am J Obstet Gynecol. 2022 Aug;227(2):296.e1-296.e18. doi: 10.1016/j.ajog.2022.02.037. Epub 2022 Mar 5.
Preterm premature rupture of membranes complicates approximately 3% of pregnancies. Currently, in the absence of chorioamnionitis or placental abruption, expectant management, including antenatal steroids for lung maturation and prophylactic antibiotic treatment, is recommended. The benefits of individualized management have not been adequately explored.
This study aimed to compare the impact of 2 different management strategies of preterm premature rupture of membranes in 2 tertiary obstetrical centers on latency of >7 days, latency to birth, chorioamnionitis, funisitis, and short-term adverse maternal and neonatal outcomes.
This was a multicenter retrospective study of women with singleton pregnancies with preterm premature rupture of membranes from 23 0/7 to 33 6/7 weeks of gestation between 2014 and 2018 and undelivered within 24 hours after hospital admission managed at Sunnybrook Health Sciences Center, Toronto, Canada (standard management group), and BCNatal (Hospital Clínic of Barcelona and Hospital Sant Joan de Déu Barcelona), Barcelona, Spain (individualized management group), following local protocols. The standard management group received similar management for all patients, which included a standard antibiotic regimen and routine maternal and fetal surveillance, whereas the individualized management group received personalized management on the basis of amniocentesis at hospital admission (if possible), to rule out microbial invasion of the amniotic cavity and targeted treatment. The exclusion criteria were cervical dilatation >2 cm, active labor, contraindications to expectant management (acute chorioamnionitis, placental abruption, or abnormal fetal tracing), and major fetal anomalies. The primary outcome was latency of >7 days, and the secondary outcomes included latency to birth, chorioamnionitis, and short-term adverse maternal and neonatal outcomes. Statistical comparisons between groups were conducted with propensity score weighting.
A total of 513 pregnancies with preterm premature rupture of membranes were included in this study: 324 patients received standard management, and 189 patients received individualized management, wherein amniocentesis was performed in 112 cases (59.3%). After propensity score weighting, patients receiving individualized management had a higher latency of >7 days (76.0% vs 41.6%; P<.001) and latency to birth (18.1±14.7 vs 9.7±9.7 days; P<.001). Although a higher rate of clinical chorioamnionitis was suspected in the individualized management group than the standard group (34.5% vs 22.0%; P<.01), there was no difference between the groups in terms of histologic chorioamnionitis (67.2% vs 73.4%; P=.16), funisitis (57.6% vs 58.1%; P=.92), or composite infectious maternal outcomes (9.1% vs 7.9%; P=.64). Prolonged latency in the individualized management group was associated with a significant reduction of preterm birth at <32 weeks of gestation (72.1% vs 90.5%; P<.001), neonatal intensive care unit admission (75.6% vs 83.0%; P=.046), and neonatal respiratory support at 28 days of life (16.1% vs 26.1%; P<.01) compared with that in the standard management group. Moreover, prolonged latency was not associated with neonatal severe morbidity at discharge (survival without severe morbidity, 80.4% vs 73.5%; P=.09).
Individualized management of preterm premature rupture of membranes may prolong pregnancy and reduce preterm birth at <32 weeks of gestation, the need for neonatal support, and neonatal intensive care unit admissions, without an increase in histologic chorioamnionitis, funisitis, neonatal infection-related morbidity, and short-term adverse maternal and neonatal outcomes.
大约 3%的妊娠会并发早产胎膜早破。目前,在没有绒毛膜羊膜炎或胎盘早剥的情况下,推荐期待治疗,包括产前类固醇促肺成熟和预防性抗生素治疗。个性化管理的益处尚未得到充分探讨。
本研究旨在比较两家三级产科中心对早产胎膜早破的两种不同管理策略对>7 天潜伏期、分娩潜伏期、绒毛膜羊膜炎、脐带炎和短期母婴不良结局的影响。
这是一项多中心回顾性研究,纳入了 2014 年至 2018 年期间妊娠 23 0/7 至 33 6/7 周、胎膜早破未在入院后 24 小时内分娩的单胎孕妇,并在加拿大多伦多的 Sunnybrook 健康科学中心(标准管理组)和西班牙巴塞罗那的 BCNatal(巴塞罗那 Clinic 和巴塞罗那 Sant Joan de Déu 医院)进行管理,根据当地方案进行个体化管理(个体化管理组)。标准管理组为所有患者提供类似的管理,包括标准抗生素方案和常规母婴监测,而个体化管理组在入院时(如有可能)进行羊膜穿刺术以排除羊水腔微生物入侵,并进行针对性治疗。排除标准为宫颈扩张>2 cm、活跃分娩、期待治疗禁忌(急性绒毛膜羊膜炎、胎盘早剥或胎儿监护异常)和主要胎儿异常。主要结局为>7 天潜伏期,次要结局包括分娩潜伏期、绒毛膜羊膜炎和短期母婴不良结局。采用倾向评分加权法进行组间比较。
本研究共纳入 513 例早产胎膜早破孕妇:324 例接受标准管理,189 例接受个体化管理,其中 112 例(59.3%)进行了羊膜穿刺术。经倾向评分加权后,接受个体化管理的患者>7 天潜伏期(76.0% vs 41.6%;P<.001)和分娩潜伏期(18.1±14.7 vs 9.7±9.7 天;P<.001)更高。尽管个体化管理组疑似临床绒毛膜羊膜炎的发生率高于标准组(34.5% vs 22.0%;P<.01),但两组间绒毛膜羊膜炎的发生率(67.2% vs 73.4%;P=.16)、脐带炎(57.6% vs 58.1%;P=.92)或复合感染性母婴结局(9.1% vs 7.9%;P=.64)无差异。个体化管理组潜伏期延长与<32 周早产(72.1% vs 90.5%;P<.001)、新生儿重症监护病房入院(75.6% vs 83.0%;P=.046)和 28 天生命新生儿呼吸支持(16.1% vs 26.1%;P<.01)显著减少相关,与标准管理组相比。此外,潜伏期延长与出院时新生儿严重发病率无相关性(无严重发病率存活率,80.4% vs 73.5%;P=.09)。
早产胎膜早破的个体化管理可能延长妊娠时间,减少<32 周的早产、新生儿支持和新生儿重症监护病房入院的需求,而不会增加组织学绒毛膜羊膜炎、脐带炎、新生儿感染相关发病率以及短期母婴不良结局。